Global Gynecology Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Feb-2017
No. of pages: 300
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Summary

The Global Gynecology Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companies

Description

Global Gynecology Partnering 2010-2017: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Gynecology partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Gynecology partnering agreement structure

Gynecology partnering contract documents

Top Gynecology deals by value

Most active Gynecology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.

The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gynecology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gynecology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gynecology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gynecology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gynecology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gynecology partnering deals by specific Gynecology target announced since 2010. The chapter is organized by specific Gynecology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gynecology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gynecology technologies and products.

Report scope

Global Gynecology Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide.

Global Gynecology Partnering 2010 to 2017 includes:

Trends in Gynecology dealmaking in the biopharma industry since 2010

Analysis of Gynecology deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Gynecology deal contract documents

Comprehensive access to over 3500 Gynecology deal records

The leading Gynecology deals by value since 2010

Most active Gynecology dealmakers since 2010

The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.

In Global Gynecology Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gynecology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 200 gynecology deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Gynecology Partnering 2010-2017: Deal trends, players and financials provides the reader with the following key benefits:

In-depth understanding of Gynecology deal trends since 2010

Access Gynecology deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Gynecology partner companies

Comprehensive access to over 750 links to actual Gynecology deals entered into by the world's biopharma companies

Indepth review of Gynecology deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Gynecology opportunities

Uncover companies actively partnering Gynecology opportunities

Global Gynecology Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gynecology dealmaking
2.1. Introduction
2.2. Gynecology partnering over the years
2.3. Gynecology partnering by deal type
2.4. Gynecology partnering by industry sector
2.5. Gynecology partnering by stage of development
2.6. Gynecology partnering by technology type
2.7. Gynecology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gynecology partnering
3.1. Introduction
3.2. Disclosed financials terms for Gynecology partnering
3.3. Gynecology partnering headline values
3.4. Gynecology deal upfront payments
3.5. Gynecology deal milestone payments
3.6. Gynecology royalty rates

Chapter 4 - Leading Gynecology deals and dealmakers
4.1. Introduction
4.2. Most active in Gynecology partnering
4.3. List of most active dealmakers in Gynecology
4.4. Top Gynecology deals by value

Chapter 5 - Gynecology contract document directory
5.1. Introduction
5.2. Gynecology partnering deals where contract document available

Chapter 6 - Gynecology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Gynecology therapeutic target
Appendices
Appendix 1 - Directory of Gynecology deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Gynecology deals by deal type 2010 to 2017
Appendix 3 - Directory of Gynecology deals by stage of development 2010 to 2017
Appendix 4 - Directory of Gynecology deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Gynecology partnering since 2010
Figure 2: Gynecology partnering by deal type since 2010
Figure 3: Gynecology partnering by industry sector since 2010
Figure 4: Gynecology partnering by stage of development since 2010
Figure 5: Gynecology partnering by technology type since 2010
Figure 6: Gynecology partnering by indication since 2010
Figure 7: Gynecology deals with a headline value
Figure 8: Gynecology deals with upfront payment values
Figure 9: Gynecology deals with milestone payment
Figure 10: Gynecology deals with royalty rates
Figure 11: Active Gynecology dealmaking activity- 2010 to 2017
Figure 12: Top Gynecology deals by value since 2010
  • Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 03-Mar-2017        Price: US 4480 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in Asi......
  • China Postmenopausal Vaginal Atrophy Treatment Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
    Published: 03-Mar-2017        Price: US 4480 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in Chi......
  • EMEA Postmenopausal Vaginal Atrophy Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 03-Mar-2017        Price: US 4480 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in EME......
  • Europe Postmenopausal Vaginal Atrophy Treatment Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 03-Mar-2017        Price: US 4480 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in Eur......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Postmenopausal Vaginal Atrophy Treatment Market 2017 Forecast to 2022
    Published: 03-Mar-2017        Price: US 4880 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in Glo......
  • Global Postmenopausal Vaginal Atrophy Treatment Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 03-Mar-2017        Price: US 3480 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in Glo......
  • North America Postmenopausal Vaginal Atrophy Treatment Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 03-Mar-2017        Price: US 4480 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in Nor......
  • United States Postmenopausal Vaginal Atrophy Treatment Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 03-Mar-2017        Price: US 4480 Onwards        Pages: 124
    Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.Scope of the Report:This report focuses on the Postmenopausal Vaginal Atrophy Treatment in Uni......
  • Endometriosis - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Mar-2017        Price: US 4950 Onwards        Pages: 85
    DelveInsight's "Endometriosis - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Endometriosis for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Endometriosis from 2013-2023. Endometriosis is the abnormal growth of endometrial tissue s......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs